TCL Archive New Biomarker Findings Show Improvement in KRAS Subtype In Phase III Erbitux Trial May 30, 2014
TCL Archive First-Line Bendamustine Doubles PFS In Non-Hodgkin and Mantle Cell Lymphoma February 22, 2013
TCL Archive Advisors Say 10 Percent Payline “Not Tenable;” All NCI Programs Must Share Budget Cuts. March 31, 2006
TCL Archive Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival July 27, 2012
